Truscreen Group (ASX:TRU) Other Long-Term Liabilities: A$-0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Truscreen Group Other Long-Term Liabilities?

Truscreen Group ASX:TRU Other Long-Term Liabilities is A$-0.00 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Truscreen Group's other long-term liabilities for the quarter that ended in Mar. 2026 was A$-0.00 Mil.

Truscreen Group's quarterly other long-term liabilities declined from Sep. 2024 (A$0.03 Mil) to Mar. 2025 (A$0.00 Mil) and declined from Mar. 2025 (A$0.00 Mil) to Mar. 2026 (A$-0.00 Mil).

Truscreen Group's annual other long-term liabilities increased from Mar. 2024 (A$0.00 Mil) to Mar. 2025 (A$0.00 Mil) but then declined from Mar. 2025 (A$0.00 Mil) to Mar. 2026 (A$-0.00 Mil).

Truscreen Group Other Long-Term Liabilities Related Terms

Truscreen Group Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Truscreen Group's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Truscreen Group Other Long-Term Liabilities Chart

Truscreen Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Truscreen Group Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.00 0.03 0.00 -0.00

Truscreen Group Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$-0.00 Mil mean?
Truscreen Group (ASX:TRU) has a Other Long-Term Liabilities of A$-0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Truscreen Group and its competitors.
Is Truscreen Group's Other Long-Term Liabilities too high?
Truscreen Group's current Other Long-Term Liabilities is A$-0.00 Mil.
How does Truscreen Group's Other Long-Term Liabilities compare to ABT and SYK?
Truscreen Group's Other Long-Term Liabilities of A$-0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Devices & Instruments company?
A good Other Long-Term Liabilities depends on the Medical Devices & Instruments industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Truscreen Group and its competitors. Truscreen Group's current Other Long-Term Liabilities is A$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current Other Long-Term Liabilities is A$-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Other Long-Term Liabilities is A$-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Truscreen Group Business Description

Other Exchanges TRU:New Zealand
Address C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.